Systemic delivery of P42 peptide: A new weapon to fight Huntington's disease

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Arribat, Yoan ^a   Talmat Amar, Yasmina ^a   Paucard, Alexia ^a   Lesport, Pierre ^a   Bonneaud, Nathalie ^a   Bauer, Caroline ^b   Bec, Nicole ^a   Parmentier, Marie Laure ^a   Benigno, Lorraine ^b   Larroque, Christian ^a   Maurel, Patrick ^b   Maschat, Florence ^a  

^a UNIV MONTPELLIER   (France)

^b Medesis Pharma   (France)

Author keywords

Huntington's disease; Microemulsion; Mouse model; Peptide

Indexed keywords

HTT PROTEIN, HUMAN; NERVE PROTEIN; P42 PEPTIDE; PEPTIDE FRAGMENT;

ANIMAL; BUCCAL DRUG ADMINISTRATION; C57BL MOUSE; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECTS; FEMALE; HELA CELL LINE; HUMAN; HUNTINGTON DISEASE; MALE; METABOLISM; MOTOR ACTIVITY; MOUSE; NERVE CELL; RECTAL DRUG ADMINISTRATION; ROTAROD TEST; SYNTHESIS;

ADMINISTRATION, BUCCAL; ADMINISTRATION, RECTAL; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; FEMALE; HELA CELLS; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; NEURONS; PEPTIDE FRAGMENTS; ROTAROD PERFORMANCE TEST;

EID: 84929465640     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/s40478-014-0086-x     Document Type: Review

References (51)

1. Zuccato C, Valenza M, Cattaneo E: Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010, 90(3):905-981.
2. Adam OR, Jankovic J: Symptomatic treatment of Huntington disease. Neurotherapeutics 2008, 5(2):181-197.
3. Busch A, Engemann S, Lurz R, Okazawa H, Lehrach H, Wanker EE: Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease. J Biol Chem 2003, 278(42):41452-41461.
4. Suhr ST, Senut MC, Whitelegge JP, Faull KF, Cuizon DB, Gage FH: Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. J Cell Biol 2001, 153(2):283-294.
5. Chai Y, Shao J, Miller VM, Williams A, Paulson HL: Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc Natl Acad Sci U S A 2002, 99(14):9310-9315.
6. Lee WC, Yoshihara M, Littleton JT: Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc Natl Acad Sci U S A 2004, 101(9):3224-3229.
7. Finkbeiner S, Mitra S: The ubiquitin-proteasome pathway in Huntington's disease. Sci World J 2008, 8: 421-433.
8. Arribat Y, Bonneaud N, Talmat-Amar Y, Layalle S, Parmentier ML, Maschat F: A huntingtin peptide inhibits polyQ-huntingtin associated defects. PLoS One 2013, 8(7):e68775.
9. Godin JD, Poizat G, Hickey MA, Maschat F, Humbert S: Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease. EMBO J 2010, 29(14):2433-2445.
10. Heng MY, Detloff PJ, Paulson HL, Albin RL: Early alterations of autophagy in Huntington disease-like mice. Autophagy 2010, 6(8):1206-1208.
11. Rockabrand E, Slepko N, Pantalone A, Nukala VN, Kazantsev A, Marsh JL, Sullivan PG, Steffan JS, Sensi SL, Thompson LM: The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet 2007, 16(1):61-77.
12. Southwell AL, Ko J, Patterson PH: Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci 2009, 29(43):13589-13602.
13. Sah DW, Aronin N: Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest 2011, 121(2):500-507.
14. Chopra V, Fox JH, Lieberman G, Dorsey K, Matson W, Waldmeier P, Housman DE, Kazantsev A, Young AB, Hersch S: A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc Natl Acad Sci U S A 2007, 104(42):16685-16689.
15. Popiel HA, Nagai Y, Fujikake N, Toda T: Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice. Neurosci Lett 2009, 449(2):87-92.
16. Dragatsis I, Levine MS, Zeitlin S: Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 2000, 26(3):300-306.
17. Leavitt BR, Guttman JA, Hodgson JG, Kimel GH, Singaraja R, Vogl AW, Hayden MR: Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet 2001, 68(2):313-324.
18. Squitieri F, Gellera C, Cannella M, Mariotti C, Cislaghi G, Rubinsztein DC, Almqvist EW, Turner D, Bachoud-Levi AC, Simpson SA, Delatycki M, Maglione V, Hayden MR, Donato SD: Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain 2003, 126(Pt 4):946-955.
19. Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, Cordelieres FP, De Mey J, MacDonald ME, Lessmann V, Humbert S, Saudou F: Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118(1):127-138.
20. Van Raamsdonk JM, Pearson J, Murphy Z, Hayden MR, Leavitt BR: Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. BMC Neurosci 2006, 7: 80.
21. Cattaneo E, Zuccato C, Tartari M: Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 2005, 6(12):919-930.
22. Mugat B, Parmentier ML, Bonneaud N, Chan HY, Maschat F: Protective role of Engrailed in a Drosophila model of Huntington's disease. Hum Mol Genet 2008, 17(22):3601-3616.
23. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP: Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87(3):493-506.
24. Rattray I, Smith E, Gale R, Matsumoto K, Bates GP, Modo M: Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/2 mouse model of HD. PLoS One 2013, 8(4):e60012.
25. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ: Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 1999, 19(8):3248-3257.
26. Wadia JS, Dowdy SF: Protein transduction technology. Curr Opin Biotechnol 2002, 13(1):52-56.
27. Joliot A, Prochiantz A: Transduction peptides: from technology to physiology. Nat Cell Biol 2004, 6(3):189-196.
28. Wadia JS, Dowdy SF: Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 2005, 57(4):579-596.
29. Mouri A, Diat O, El Ghzaoui A, Bauer C, Maurel JC, Devoisselle JM, Dorandeu C, Legrand P: Phase behavior of reverse microemulsions based on Peceol((R)). J Colloid Interface Sci 2014, 416: 139-146.
30. Pouladi MA, Brillaud E, Xie Y, Conforti P, Graham RK, Ehrnhoefer DE, Franciosi S, Zhang W, Poucheret P, Compte E, Maurel JC, Zuccato C, Cattaneo E, Neri C, Hayden MR: NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiol Dis 2012, 48: 282-289.
31. Sittler A, Walter S, Wedemeyer N, Hasenbank R, Scherzinger E, Eickhoff H, Bates GP, Lehrach H, Wanker EE: SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. Mol Cell 1998, 2(4):427-436.
32. Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, Kurosawa M, Nekooki M, Nukina N: Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 2004, 10(2):148-154.
33. Rodriguez-Navarro JA, Rodriguez L, Casarejos MJ, Solano RM, Gomez A, Perucho J, Cuervo AM, Garcia de Yebenes J, Mena MA: Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. Neurobiol Dis 2010, 39(3):423-438.
34. Khafagy ES, Morishita M: Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev 2012, 64: 531-539.
35. Sieuwerts AM, Klijn JG, Peters HA, Foekens JA: The MTT tetrazolium salt assay scrutinized: how to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival. Eur J Clin Chem Clin Biochem 1995, 33(11):813-823.
36. Drexler DM, Garrett TJ, Cantone JL, Diters RW, Mitroka JG, Prieto Conaway MC, Adams SP, Yost RA, Sanders M: Utility of imaging mass spectrometry (IMS) by matrix-assisted laser desorption ionization (MALDI) on an ion trap mass spectrometer in the analysis of drugs and metabolites in biological tissues. J Pharmacol Toxicol Methods 2007, 55(3):279-288.
37. Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A: Huntington's disease: the current state of research with peripheral tissues. Exp Neurol 2009, 219(2):385-397.
38. Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF: Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 2002, 22(5):1592-1599.
39. Costanzo M, Abounit S, Marzo L, Danckaert A, Chamoun Z, Roux P, Zurzolo C: Transfer of polyglutamine aggregates in neuronal cells occurs in tunneling nanotubes. J Cell Sci 2013, 126(Pt 16):3678-3685.
40. Tam S, Spiess C, Auyeung W, Joachimiak L, Chen B, Poirier MA, Frydman J: The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. Nat Struct Mol Biol 2009, 16(12):1279-1285.
41. Yamamoto A, Lucas JJ, Hen R: Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000, 101(1):57-66.
42. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S: Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431(7010):805-810.
43. Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR: Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013, 12(7):637-649.
44. Mihm MJ, Amann DM, Schanbacher BL, Altschuld RA, Bauer JA, Hoyt KR: Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2007, 25(2):297-308.
45. Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, Artates JW, Weiss A, Cheng SH, Shihabuddin LS, Hung G, Bennett CF, Cleveland DW: Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012, 74(6):1031-1044.
46. Nagai Y, Tucker T, Ren H, Kenan DJ, Henderson BS, Keene JD, Strittmatter WJ, Burke JR: Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. J Biol Chem 2000, 275(14):10437-10442.
47. Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M, Washington SL, Maxwell MM, Marsh JL, Thompson LM, Wanker EE, Young AB, Housman DE, Bates GP, Sherman MY, Kazantsev AG: A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A 2005, 102(3):892-897.
48. Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, Messer A: Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci U S A 2005, 102(32):11563-11568.
49. Southwell AL, Khoshnan A, Dunn DE, Bugg CW, Lo DC, Patterson PH: Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J Neurosci 2008, 28(36):9013-9020.
50. Bauer PO, Goswami A, Wong HK, Okuno M, Kurosawa M, Yamada M, Miyazaki H, Matsumoto G, Kino Y, Nagai Y, Nukina N: Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat Biotechnol 2010, 28(3):256-263.
51. Butler DC, McLear JA, Messer A: Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins. Prog Neurobiol 2012, 97(2):190-204.